Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil - Wikidata - wikimedia - TriplyDB

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil

http://www.wikidata.org/entity/Q57212252

about

Paroxetine versus other anti-depressive agents for depression Duloxetine versus other anti-depressive agents for depression Association between Painful Physical Symptoms and Clinical Outcomes in Korean Patients with Major Depressive Disorder: A Three-Month Observational Study.A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.Analysing psychosocial difficulties in depression: a content comparison between systematic literature review and patient perspective Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Efficacy comparison of duloxetine and SSRIs at doses approved in Japan.Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression: Double-Blind, Randomized Non-Inferiority Trial Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial.The effect of initial duloxetine dosing strategy on nausea in korean patients with major depressive disorder Prediction of response within the first 3 days to treatment with paroxetine for depression Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.Adverse reactions to duloxetine in depression.Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis.Non-inferiority margins employed in clinical trials in Japan.An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator.A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials.Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.

P2860

Q24197507-7C5E5687-26B3-4DDA-8112-99915567624A Q24198808-22DD65AB-C1B4-4C84-B76B-6C4593D83F8C Q33600302-99A9A52E-D419-48EC-858B-85C9E61EE8C8 Q33689953-9E3E7814-BDC1-4AA8-92E1-7B431212A1E0 Q33804038-26CCAC04-04EE-4DE1-90DC-A034208E4C23 Q34590507-6FC2AAE9-2AE1-4F03-AA0C-6644F558359A Q34977592-811E2F45-2683-4A25-A277-67111366D16B Q35061870-5D84076E-1E25-44B0-8028-CA28929F67C2 Q35105942-ED4F7DD3-ED3A-40FA-947A-56D1E5DF0B76 Q35162633-B3D03C14-46FA-4B3C-BE1A-4415E06196B8 Q36208764-D561588F-744E-4F39-BA0C-338B72D07244 Q36463507-0DD55289-65D6-43F1-B5A0-A2ECEBC251D9 Q36538423-D3D7A3E1-0E80-4B09-AD46-C0CD6C8B80BF Q36968908-DBDC61A1-8DC5-4BB6-A53B-C5615427342C Q37503551-E21586D7-4548-4D39-9415-539CC55A38ED Q37872294-49D541FE-7818-4613-8D95-92225A5D92FA Q38476909-CD3F252E-D1E7-4184-ABC1-5E70AB9375A1 Q38570635-93C316C6-C478-470F-9010-28316DA76129 Q41347942-3BEE5FB2-2E10-4217-B995-8BD632B0BC78 Q41366996-A0FC5261-B926-436A-B78F-A0AB04441362 Q46377304-27C8887D-2AC3-498B-BEEA-1BB985B5EF99 Q47165527-8391CB0E-56F3-468C-9340-06B24408269E Q48058387-933CFC35-E7CE-4154-8FF5-D0981DE717E0

P2860

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil

http://www.wikidata.org/entity/Q57212252

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в червні 2007

@uk

name

Once-daily duloxetine 60 mg in ...... hina, Korea, Taiwan and Brazil

@en

Once-daily duloxetine 60 mg in ...... hina, Korea, Taiwan and Brazil

@nl

type

label

Once-daily duloxetine 60 mg in ...... hina, Korea, Taiwan and Brazil

@en

Once-daily duloxetine 60 mg in ...... hina, Korea, Taiwan and Brazil

@nl

prefLabel

Once-daily duloxetine 60 mg in ...... hina, Korea, Taiwan and Brazil

@en

Once-daily duloxetine 60 mg in ...... hina, Korea, Taiwan and Brazil

@nl

P1433

Q57212252-F6F44739-16BC-4CDE-8439-D6A1347FC2E5

P1476

Q57212252-B46F36A3-3AB7-48CF-ADBA-2A094F97A9FC

P2093

Q57212252-23D78917-C302-40CB-835D-06F7CEC5A338

Q57212252-48388E95-2D0A-4496-9B88-1FDA46270013

Q57212252-5B74F42B-2B61-4E71-B5A0-D81FA9FEB2AC

Q57212252-778F5CEB-A908-490D-8405-791FF228FEBA

Q57212252-788F204B-DF0B-4B59-B0D2-4500590F2558

Q57212252-93E1275D-D29F-4469-8F54-D71E9DAF85BE

Q57212252-B5D39A73-6624-4D23-BC6E-FB2919FE2305

Q57212252-B77B238A-2A9F-400B-B456-338D1963CDCD

Q57212252-BD59A06A-893B-4BC7-B1AA-44876427AE41

Q57212252-DF847ACE-9F3A-4F83-8086-F749EA3233D7

P2860

Q57212252-07883942-3BC5-4FCB-B153-CC495A9D02D6

Q57212252-11837C0E-392C-46AD-A9CE-3084E348BD4A

Q57212252-12A3A9B1-4B8A-437C-A176-98B5CA181068

Q57212252-235E5F62-A79C-4AE5-B1DD-EA74AFB95386

Q57212252-3779B100-5005-4093-A78B-E9F3777E6438

Q57212252-3B0F2D82-FC62-4D57-8056-56EA66B811EB

Q57212252-45F9EE3A-46B8-4821-88E4-D40E208670C1

Q57212252-69AF0032-9CDA-48AF-9CEC-874815B48E5E

Q57212252-75444365-42B2-4FA8-8F06-69C46153B466

Q57212252-7724648E-E991-45D7-8C36-1C5ECA64CFED

P304

Q57212252-17B19CCA-AE3C-417B-8339-287479533AD6

P31

Q57212252-BBAFA878-B919-4C0D-8C38-7CB415CDB335

P356

Q57212252-C429D1AC-2144-4CA5-A10E-BA1934284E0A

P407

Q57212252-B06B9C90-D67C-48EB-97B6-02A3C4C21837

P433

Q57212252-EEA3E865-4525-41E9-A3A6-5A44A4804BEA

P478

Q57212252-4DACDF0A-1EDC-48F5-8DA4-A5A17B2C4B0D

P50

Q57212252-2AFBB620-2637-4B9F-917C-91FBC9DD1C7D

P577

Q57212252-2B391E5F-9500-48AE-B6B3-6FFC6FED3E65

P698

Q57212252-EC043C9D-2B69-40B4-87F2-5024C830D78B

P356

J.1440-1819.2007.01666.X

P1433

Psychiatry and Clinical Neurosciences

P1476

Once-daily duloxetine 60 mg in ...... hina, Korea, Taiwan and Brazil

@en

P2093

Chia-Yih Liu

http://www.w3.org/2001/XMLSchema#string

Gavan A Harrison

http://www.w3.org/2001/XMLSchema#string

Jin Pyo Hong

http://www.w3.org/2001/XMLSchema#string

Joel Raskin

http://www.w3.org/2001/XMLSchema#string

Liang Shu

http://www.w3.org/2001/XMLSchema#string

Min Soo Lee

http://www.w3.org/2001/XMLSchema#string

Phil Lee

http://www.w3.org/2001/XMLSchema#string

Samuel A Colman

http://www.w3.org/2001/XMLSchema#string

Sandra Ruschel

http://www.w3.org/2001/XMLSchema#string

Xiufeng Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.

Efficacy of newer medications for treating depression in primary care patients.

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression.

Duloxetine vs. placebo in patients with painful diabetic neuropathy.

P304

295-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1819.2007.01666.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17472599

http://www.w3.org/2001/XMLSchema#string